* Cassava Sciences press release [https://seekingalpha.com/pr/20200807-cassava-reports-q2-2025-financials-results-and-provides-business-update] (NASDAQ:SAVA [https://seekingalpha.com/symbol/SAVA]): Q2 GAAP EPS of -$0.92.
* Cash and cash equivalents were $112.4 million, with no debt, as of June 30, 2025. This compares to cash and cash equivalents of $128.6 million as of December 31, 2024.
MORE ON CASSAVA SCIENCES
* Cassava Sciences taps Joseph Hulihan as chief medical officer [https://seekingalpha.com/news/4481261-cassava-sciences-taps-joseph-hulihan-as-chief-medical-officer]
* Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit [https://seekingalpha.com/news/4452904-editas-medicine-cassava-sciences-among-healthcare-stocks-to-join-russell-microcap-mnkd-ocgn-to-exit]
* Financial information for Cassava Sciences [https://seekingalpha.com/symbol/SAVA/income-statement]
Cassava Sciences GAAP EPS of -$0.92
Published 2 months ago
Aug 14, 2025 at 11:41 AM
Positive
Auto